Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis

Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR mutations (EGFR-M+). Patients and methods: We conducted a literature-based meta-analysis to quantify the magnitude of b...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Bria, E., Milella, M., Cuppone, F., Novello, S., Ceribelli, A., Vaccaro, V., Sperduti, I., Gelibter, A., Scagliotti, G. V., Cognetti, F., Giannarelli, D.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2011
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3202146/
https://ncbi.nlm.nih.gov/pubmed/21325444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdq742
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg